Potential treatment for rare autoimmune disorder adapted from CAR-T therapy in study
Evidence from a small-scale clinical trial suggests that a variation of the blood cancer immunotherapy chimeric antigen receptor T-cell (CAR-T) could be adapted to treat myasthenia gravis (MG), an autoimmune disorder of the nervous system. Read More
NIH funds work to develop protocol for re-administration of DMD gene therapies
The National Institutes of Health (NIH) is funding work that could show how the immune system reacts to muscle disease gene therapies and lead to a protocol for re-administration of the treatments. Read More
Biomarker predicts response to chemo-immunotherapy in lung cancer patients
Researchers have found a biomarker that provides an early indication of whether a patient is responding to chemo-immunotherapy. Read More
Novel glioblastoma treatment shows promising results
Toronto’s University Health Network (UHN) neurosurgeons have developed a novel glioblastoma therapy that combines the injection of an oncolytic virus directly into the tumor with intravenous immunotherapy. The results, published Monday in Nature Medicine, found that this combination therapy prolonged survival rates, providing clinical benefits to over half of the patients studied. Read More
Driver of responses to checkpoint inhibitors suggests way to improve cancer therapy
Expansion of a diverse subset of T-cell clones influences how patients respond to immune checkpoint inhibitors (ICIs), suggesting it may be possible to predict who will benefit from the treatments. Read More
Initial colon cancer surgery may not be best course
Southern China researchers unexpectedly found pre-surgery immunotherapy for a common type of colorectal cancer even more effective at early and mid-stages than its previously known high success rate in the metastatic stage of the disease. The study, published January 11 in JNCCN - Journal of the National Comprehensive Cancer Network, found that immune checkpoint programmed cell death 1 (PD-1) inhibitor treatment prior to surgery was significantly effective for patients with certain types of colorectal cancer. Read More
Exhausted cancer-killing cells help tumors by suppressing the immune system, study finds
Exhausted T cells switch from attacking to helping cancers in low-oxygen environments, pointing to a new way to improve the efficacy of immuno-oncology drugs, according to a study published on Wednesday in Nature Immunology. Read More
Inhibiting white blood cell enzyme reduces lung metastases in mice: study
Researchers at The Wistar Institute and Jubilant Therapeutics have found an enzyme in neutrophils that promotes tumor growth and metastasis, pointing to a new way to treat cancers. Read More
Stanford platform improves hunt for antigens that trigger strong immune responses
Researchers at Stanford University have developed a method for making faster, more accurate predictions of which antigens will trigger a strong immune response. Their work could help scientists develop more effective cancer immunotherapies. Read More
Blocking key enzyme boosts anticancer T-cell responses, resistance to immunosuppression
Blocking a key enzyme boosts anticancer T-cell responses and resistance to immunosuppression, according to a mice study from LSU Health New Orleans published August 26 in Frontiers in Immunology. Read More
Conferences
Science Briefs
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
